Lewandowski Kathryn E, Bouix Sylvain, Ongur Dost, Shenton Martha E
Schizophrenia and Bipolar Disorder Program, McLean Hospital, Belmont, MA 02478, USA.
Department of Psychiatry, Harvard Medical School, Boston, MA 02215, USA.
J Psychiatr Brain Sci. 2020;5. doi: 10.20900/jpbs.20200002. Epub 2020 Feb 11.
Psychotic disorders are severe, debilitating, and even fatal. The development of targeted and effective interventions for psychosis depends upon on clear understanding of the timing and nature of disease progression to target processes amenable to intervention. Strong evidence suggests early and ongoing neuroprogressive changes, but timing and inflection points remain unclear and likely differ across cognitive, clinical, and brain measures. Additionally, granular evidence across modalities is particularly sparse in the "bridging years" between first episode and established illness-years that may be especially critical for improving outcomes and during which interventions may be maximally effective. Our objective is the systematic, multimodal characterization of neuroprogression through the early course of illness in a cross-diagnostic sample of patients with psychosis. We aim to (1) interrogate neurocognition, structural brain measures, and network connectivity at multiple assessments over the first eight years of illness to map neuroprogressive trajectories, and (2) examine trajectories as predictors of clinical and functional outcomes. We will recruit 192 patients with psychosis and 36 healthy controls. Assessments will occur at baseline and 8- and 16-month follow ups using clinical, cognitive, and imaging measures. We will employ an accelerated longitudinal design (ALD), which permits ascertainment of data across a longer timeframe and at more frequent intervals than would be possible in a single cohort longitudinal study. Results from this study are expected to hasten identification of actionable treatment targets that are closely associated with clinical outcomes, and identify subgroups who share common neuroprogressive trajectories toward the development of individualized treatments.
精神障碍严重、使人衰弱甚至致命。针对精神病的有针对性且有效的干预措施的发展取决于对疾病进展的时间和性质的清晰理解,以便针对适合干预的过程。有力证据表明存在早期且持续的神经进展性变化,但时间和转折点仍不明确,并且在认知、临床和脑测量方面可能存在差异。此外,在首次发作和确诊疾病之间的“过渡年”,跨模态的详细证据尤其稀少,而这几年对于改善预后可能尤为关键,在此期间干预可能最为有效。我们的目标是在精神病患者的跨诊断样本中,通过疾病早期过程对神经进展进行系统的多模态表征。我们旨在(1)在疾病的头八年进行多次评估,询问神经认知、脑结构测量和网络连通性,以绘制神经进展轨迹,以及(2)检查这些轨迹作为临床和功能结果的预测指标。我们将招募192名精神病患者和36名健康对照。使用临床、认知和成像测量在基线以及8个月和16个月随访时进行评估。我们将采用加速纵向设计(ALD),与单一队列纵向研究相比,该设计允许在更长的时间范围内以更频繁的间隔确定数据。预计这项研究的结果将加速确定与临床结果密切相关的可采取行动的治疗靶点,并识别出具有共同神经进展轨迹的亚组,以开发个性化治疗。